Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas

BACKGROUND: Uterine and ovarian carcinosarcomas (CS) are rare cancers with poor prognosis. Sacituzumab-govitecan (SG) is a new class of antibody-drug-conjugate (ADC) targeting the human-trophoblast-cell-surface marker (Trop-2) conjugated with the active metabolite of irinotecan (SN-38). We evaluated...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Lopez, Salvatore, Perrone, Emanuele, Bellone, Stefania, Bonazzoli, Elena, Zeybek, Burak, Han, Chanhee, Tymon-Rosario, Joan, Altwerger, Gary, Menderes, Gulden, Bianchi, Anna, Zammataro, Luca, Manzano, Aranzazu, Manara, Paola, Ratner, Elena, Silasi, Dan-Arin, Huang, Gloria S., Azodi, Masoud, Schwartz, Peter E., Raspagliesi, Francesco, Angioli, Roberto, Buza, Natalia, Hui, Pei, Bond, Heather M., Santin, Alessandro D.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2020
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7007291/
https://ncbi.nlm.nih.gov/pubmed/32082489
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27342
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia